Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia

This study has been completed.
Information provided by (Responsible Party):
Innate Pharma Identifier:
First received: December 7, 2010
Last updated: February 27, 2014
Last verified: February 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2013
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)